ASweetLife Team
ASweetLife Team

Amylin Lilly Logo

Victoza: The Earlier The Better, New Study Shows

New data presented at the European Association for the Study of Diabetes (EASD) shows a significantly higher proportion of patients reached target HbA1c levels of <7% when Victoza (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or had previously received only one oral anti-diabetic drug (OAD)...
0 Shares
Amylin Lilly Logo

Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...
0 Shares

Photo Contest! Win a Nova Max Plus Glucose Meter and Test Strips

For all you diabetes slobs out there looking to clean up your diabetes act, here's your chance. ASweetLife has teamed up with Nova Diabetes Care, maker of the Nova Max Plus Glucose Monitoring System, for a contest/giveaway. We're offering you a chance to win one of two Nova Max Plus glucose meters/ketone testers.
0 Shares
JDRF New Logo

JDRF Announces $100,000 Challenge for Development of Glucose Responsive Insulin

The Juvenile Diabetes Research Foundation (JDRF) and InnoCentive, Inc., the pioneer in open innovation and crowdsourcing, announced a $100,000 Challenge calling for innovative ways to approach the discovery and development of a glucose-responsive insulin drug as a means to treat insulin-dependent diabetes. The Challenge is open to the public and can be found on the InnoCentive website...
0 Shares
JDRF New Logo

New Drug Target for Promoting Beta Cell Regeneration Discovered

JDRF-funded researchers in collaboration with Hoffmann-La Roche pharmaceutical company have discovered a protein that regulates beta cell growth and a chemical compound that stimulates it. The discovery represents a significant advance in identifying a new drug target for beta cell regeneration...
0 Shares
Perfect OneHundredBG

One Hundred BG: Send In Yours

Gary Schmidt was diagnosed with type 1 diabetes in 2002 at the age of 29. Three years ago he started running and has since completed three marathons, a Half Ironman (a Full Ironman is in the works for 2012) and many other races and triathlons. He's involved with Insulindependence...
0 Shares

Wild Salmon with Basil Aioli and Quinoa

When we came across this incredible recipe for wild salmon with basil aioli and quinoa, we had to get in touch with Marla Meridith of Family Fresh Cooking and ask for permission to share it. We're delighted she agreed. Thank you, Marla!
0 Shares

Lilly’s New Type 2 Diabetes Drug Receives EU Approval

The new type 2 diabetes drug Trajenta (linagliptin 5 mg film-coated tablets) received Marketing Authorization from the European Commission for the treatment of type 2 diabetes. The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea. Linagliptin is also approved for use as monotherapy in patients...
0 Shares
PositiveID - logo

PositiveID Completes Phase II Testing Of GlucoChip, a Glucose-Sensing Microchip

PositiveID announced it has successfully completed Phase II testing of its GlucoChip™, a glucose-sensing microchip for diabetes patients. In Phase II, the Company, in conjunction with its development partner RECEPTORS LLC, created and demonstrated a stable and reproducible, closed-cycle...
0 Shares